Gary Gibson, Ph.D., of the Burke Medical Research Institute has been appointed to the Scientific Review Board of the Alzheimer’s Drug Discovery Foundation (ADDF). The ADDF provides seed funding to scientists conducting cutting-edge drug discovery and clinical research. The Scientific Review Board consists of over 150 experts in the field of Alzheimer’s research and is tasked with reviewing all grant applications submitted to the ADDF. Since its founding in 1998, the ADDF has invested more than $66 million in Alzheimer’s research at academic centers and biotechnology companies in 18 countries. According to the foundation, 5.4 million Americans currently live with Alzheimer’s disease and the number is expected to triple by 2050.
Dr. Gibson is director of the Laboratory for Mitochondrial Biology and Metabolic Dysfunction in Neurodegeneration at BMRI where his research focuses on the underlying causes of age-related neurodegenerative diseases and the development of effective therapies.